Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DA-2802 vs Viread in Chronic Hepatitis B
NCT02967939Phase 3Completed
- Sponsor
- Dong-A ST
- Start
- Mar 2017
- Primary completion
- Jan 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of tenofovir disoproxil orotate in Chronic Hepatitis B (CHB) (2 arms), sponsored by Dong-A ST. Primary endpoint: Difference of HBV DNA level (log10) at 48 weeks. Started Mar 2017; status: completed.
02
Drugs
tenofovir disoproxil orotate
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on NCT02967939.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02967939.